MedTrace Logo

Essential Amino Acid Supplementation in Older Adult COVID-19 Patients

NCT04816071 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2024-09-03

No results posted yet for this study

Summary

A 4-week treatment of essential amino acids or placebo to participants with: 1) negative COVID-19 test with exposure, or 2) positive COVID-19 test and no or mild symptoms. The study team will measure change in symptoms. Participants will complete symptom surveys for 4 weeks and once at 8 and 12 weeks as well as pre- and post-assessments.

Conditions

  • Covid19

Interventions

DRUG

Essential amino acids

Dietary Supplement

DIETARY_SUPPLEMENT

Maltodextrin

Control

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Gohar Azhar, MD · University of Arkansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2021-05-01
Completion
2021-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04816071 on ClinicalTrials.gov